Human in vivo research on the vascular effects of adenosine

European Journal of Pharmacology
Niels P RiksenPaul Smits

Abstract

In situations of impending tissue danger, such as during ischaemia, the concentration of the endogenous purine nucleoside adenosine rapidly increases. Subsequent stimulation of G-protein coupled adenosine receptors induces several cardiovascular effects, such as vasodilation, inhibition of inflammation, modulation of sympathetic nervous system activity, and increasing myocardial tolerance against ischaemia-reperfusion, which are all aimed at protecting the affected tissue. Although animal models have consistently shown profound cardiovascular protection by adenosine, up to now translation of this knowledge into clinical practice is limited. This current review is focused on human in vivo studies on the cardiovascular effects of adenosine. Several techniques, such as microdialysis, venous occlusion plethysmography, and (99m)Tc-annexin A5 scintigraphy can be used to study these effects of adenosine in healthy volunteers in vivo. By use of these techniques, recent studies have shown that the cardiovascular effects of adenosine can be modulated by genetic factors (e.g. a single nucleotide polymorphism in the gene encoding for adenosine monophosphate deaminase), by metabolic factors (e.g. by the plasma homocysteine concentration), a...Continue Reading

References

Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T MorisakiE W Holmes
Sep 1, 1990·Proceedings of the Society for Experimental Biology and Medicine·W P McCann, R E Katholi
Aug 1, 1987·Journal of Cardiovascular Pharmacology·P SmitsA van 't Laar
Jul 1, 1989·Progress in Cardiovascular Diseases·L BelardinelliR M Berne
Aug 1, 1989·The Journal of Clinical Investigation·D A CoxP Ganz
Mar 1, 1987·Acta Physiologica Scandinavica·T B ConradsonP J Barnes
Apr 15, 1981·The Biochemical Journal·J SchraderH Bardenheuer
Apr 1, 1994·The Journal of Clinical Investigation·F Costa, I Biaggioni
May 1, 1996·Cardiovascular Research·R S Vander Heide, K A Reimer
Jan 1, 1997·Clinical Science·G A RongenP Smits
Mar 21, 1998·The Journal of Clinical Investigation·G A RongenJ S Floras
May 12, 1998·Hypertension·F Costa, I Biaggioni
Jun 19, 1998·The American Journal of Cardiology·G A RongenJ S Floras
Mar 2, 1999·American Journal of Respiratory and Critical Care Medicine·H SaitoY Kawakami
Oct 12, 2000·Journal of the American College of Cardiology·J L AndersonN Hart
Dec 9, 2000·Naunyn-Schmiedeberg's Archives of Pharmacology·A Deussen
Mar 9, 2002·BMJ : British Medical Journal·Markus Müller
Oct 26, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Homocysteine Studies Collaboration
Jan 16, 2003·Arthritis and Rheumatism·M Carmen MontesinosBruce N Cronstein
Jun 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karen AlseneHarriet de Wit
Jul 16, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Zhi-Qing ZhaoJakob Vinten-Johansen
Oct 17, 2003·American Journal of Physiology. Heart and Circulatory Physiology·John P HeadrickKevin J Ashton
Feb 11, 2005·Molecular Pharmacology·Joel Linden
Apr 9, 2005·Journal of Applied Physiology·Niels P RiksenGerard A Rongen
Jun 1, 2005·Trends in Immunology·Michail V Sitkovsky, Akio Ohta
Jun 14, 2005·Cardiovascular Research·Hajime KinJakob Vinten-Johansen

❮ Previous
Next ❯

Citations

Aug 13, 2011·Journal of Cardiothoracic and Vascular Anesthesia·Ismihan Selen OnanIlhan Sanisoglu
May 13, 2010·Journal of Biomedical Optics·Matthew P FronheiserAlexander A Oraevsky
Jul 11, 2012·The Journal of Pharmacy and Pharmacology·Stephanie L M TayLai Wah Chan
Nov 25, 2014·Paediatric and Perinatal Epidemiology·Martha M WerlerAllen A Mitchell
Nov 12, 2015·Pharmacogenomics·Rayan SaabRolf P Kreutz
Dec 30, 2015·Pacing and Clinical Electrophysiology : PACE·Peter MitroGabriel Valocik
Jan 8, 2013·European Journal of Nutrition·Diana F Serapiao-MoraesTatiane S Faria
Mar 7, 2012·Expert Review of Clinical Pharmacology·Niels P Riksen, Gerard A Rongen
Dec 26, 2019·The Tohoku Journal of Experimental Medicine·Kenta FujimotoMasaaki Inaba
Feb 6, 2020·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Ryan Rosenberry, Michael D Nelson
Jul 14, 2016·European Journal of Applied Physiology·Carl A JamesNeil S Maxwell
Oct 20, 2010·Renal Failure·Guglielmo M TrovatoDaniela Catalano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here